6.6
Agonisti Adrenergici: Agenti ad Azione Indiretta
Gli agonisti adrenergici ad azione indiretta potenziano gli effetti delle catecolamine endogene attraverso meccanismi diversi senza legarsi direttamen…
Gli agonisti adrenergici ad azione indiretta potenziano l'effetto delle catecolamine endogene attraverso vari meccanismi.
Agonisti come l'anfetamina e la tiramina sono definiti "dislocatori" in quanto inducono il rilascio di catecolamine esaurendo le loro riserve dalla vescicola sinaptica.
Assomigliano alla noradrenalina ma mancano di una porzione catecolare. A causa di questa somiglianza, vengono attivamente trasportati nei vasi sinaptici e, alla fine, sostituiscono la noradrenalina.
La noradrenalina citosolica viene quindi scambiata con un'altra molecola dislocatore e rilasciata per agire sugli adrenocettori postsinaptici.
Un altro meccanismo coinvolge l'inibizione della ricaptazione delle catecolamine. La cocaina blocca il trasportatore coinvolto nella ricaptazione delle catecolamine, potenziando così l'azione simpaticomimetica.
Inoltre, la selegilina, un inibitore delle MAO, e l'entacapone, un inibitore delle COMT, sono simpaticomimetici ad azione indiretta in quanto impediscono il metabolismo e la successiva escrezione delle catecolamine circolanti.
Gli agonisti ad azione indiretta come la cocaina e l'anfetamina sono spesso abusati a causa dei loro effetti centrali, come l'euforia derivante dal rilascio di dopamina e serotonina.
View the full transcript and gain access to JoVE Core videos
Q1: How do displacer drugs like amphetamine and tyramine work as indirect-acting agonists?
Displacers resemble noradrenaline but lack a catechol moiety, allowing active transport into synaptic vesicles. Once inside, they replace stored noradrenaline, which is then released to act on postsynaptic adrenoceptors. This mechanism enhances sympathomimetic effects without directly binding to receptors. Amphetamine and tyramine exemplify this displacement strategy.
Q2: What is the mechanism by which cocaine acts as an indirect-acting sympathomimetic?
Cocaine blocks the transporter responsible for catecholamine reuptake, preventing noradrenaline and dopamine from being removed from the synaptic cleft. This potentiates sympathomimetic action by prolonging neurotransmitter availability at adrenoceptors. As a local anesthetic with reuptake-inhibiting properties, cocaine produces both peripheral and central nervous system effects.
Q3: How do MAO inhibitors and COMT inhibitors enhance catecholamine effects?
MAO inhibitors like selegiline and COMT inhibitors like entacapone prevent the breakdown and excretion of circulating catecholamines. By blocking these metabolic pathways, these enzyme inhibitors increase catecholamine concentration and duration of action, indirectly potentiating sympathomimetic responses without directly activating adrenoceptors.
Q4: Why do amphetamine and cocaine have abuse potential despite their pharmacological differences?
Both amphetamine and cocaine stimulate central nervous system effects, particularly dopamine and serotonin release, producing euphoria and reward sensations. Although they use different mechanisms—displacement versus reuptake inhibition—both drugs enhance monoamine availability in the brain, driving their addictive potential and abuse liability.
Q5: What structural feature distinguishes displacer agonists from direct-acting adrenergic agonists?
Displacer agonists like amphetamine and tyramine lack a catechol moiety present in noradrenaline and direct-acting agents. This structural difference enables their active transport into synaptic vesicles, improves oral bioavailability, and enhances central nervous system penetration. The absence of the catechol group is essential to their displacement mechanism.
Q6: How does tyramine in fermented foods interact with MAO inhibitor medications?
Tyramine, a displacer agonist found in fermented foods, mimics sympathetic responses by releasing stored catecholamines. When individuals take MAO inhibitors, tyramine metabolism is blocked, causing excessive accumulation and potentiation of sympathomimetic effects. This interaction can produce dangerous hypertensive responses, making dietary tyramine restriction important during MAO inhibitor therapy.
Q7: What distinguishes indirect-acting agonists from direct-acting agents in their mechanism of action?
Indirect-acting agonists enhance endogenous catecholamine effects through displacement, reuptake inhibition, or enzyme inhibition rather than directly binding to adrenoceptors. Direct-acting agents bind directly to adrenoceptors to produce their effects. Indirect agents potentiate existing neurotransmitter activity, while direct agents independently activate receptors.